AlertEdge.io
Single-Ticker Trade Brief
ABT — Abbott Laboratories Report Date: 2026-08-24 13:30 UTC  |  Sector: Health Care  |  Rating:
RISK DISCLAIMER: This is an automated breakout signal. Always validate before entering a position.
▲ Breakout Signal — Volume Confirmed

ABT closed above the $116.58 breakout level on 1.58x average volume. ATR-based levels set automatically. Next resistance target: $120.38.

Ticker
ABT
Entry Price
$116.64
Breakout Level
$116.58
Stop Loss
$114.71
TP1 Target
$120.38
TP2 Target
$122.88
Risk / Reward
1 : 1.95
1.58x avg volume
View ABT Chart on TradingView

Key Price Levels

TP1 Target
$120.38
Breakout Level
$116.58
Entry
$116.64
Stop Loss
$114.71

Fundamentals

P/E Ratio
37.757282
EPS (TTM)
3.09
Dividend Yield
216.0%
52-Wk High
137.49
52-Wk Low
81.97
Beta
0.581

Deep Dive Analysis — Claude Sonnet

ALERTEDGE TRADE BRIEF — ABT (Abbott Laboratories)

Generated by AlertEdge.io

SETUP

ABT is pressing against the $116.58 breakout level with the bar closing essentially at the high of $116.65. Volume came in at 1.58x average, providing modest confirmation. The risk/reward of 1:1.95 is acceptable, with TP1 at $120.38 and TP2 at $122.88 against a $114.71 stop. However, the live price has already slipped back to $116.54, sitting fractionally below the breakout trigger. Entry here requires a clear reclaim and hold above $116.58 on follow-through — do not chase below the line.

CATALYSTS

ABT has beaten earnings in four of the last five quarters with the most recent April 2026 beat of $1.09 vs $1.07 est providing a clean fundamental backdrop. The $670M NEC formula settlement removes a significant litigation overhang that had been weighing on the stock. Insider buying is notable — multiple directors and an officer collectively purchased over $1.7M in shares across April through August 2026, signaling internal confidence. MedTech sector comparisons versus peers like Intuitive Surgical and Thermo Fisher suggest ABT is being evaluated for relative value, which could attract rotation.

RISKS

The signal quality score of 50/100 is the primary concern — this is an average setup, not a clean early-in-move entry. ABT sits nearly 15% below its 52-week high of $137.49, meaning overhead supply is significant across that entire range. The P/E of 37.8x on EPS of $3.09 is stretched for a low-beta defensive name, leaving limited margin for disappointment. The live price failing to hold above the breakout level at signal time is a real-time red flag — momentum is not confirming. Next earnings are not until October 2026, so no near-term catalyst to force a directional move.

CONVICTION: Medium — The insider buying cluster and litigation resolution are genuine positives, but the below-average signal quality score, price slipping back under the breakout level, and heavy overhead resistance keep this from being a high-conviction setup.

Stop: $114.71 | TP1: $120.38 | TP2: $122.88

Wait for a confirmed close or intraday hold above $116.58 before adding size.